Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. [electronic resource]

By:

Jodele, Sonata

Contributor(s):

Fukuda, Tsuyoshi
Mizuno, Kana
Vinks, Alexander A
Laskin, Benjamin L
Goebel, Jens
Dixon, Bradley P
Chima, Ranjit S
Hirsch, Russel
Teusink, Ashley
Lazear, Danielle
Lane, Adam
Myers, Kasiani C
Dandoy, Christopher E
Davies, Stella M

Producer: 20161102Description: 307-315 p. digitalISSN:

1523-6536

Subject(s):

Antibodies, Monoclonal, Humanized -- administration & dosage
Female
Hematopoietic Stem Cell Transplantation -- adverse effects
Humans
Male
Metabolic Clearance Rate
Thrombotic Microangiopathies -- drug therapy
Transplantation Conditioning -- adverse effects

Online resources:

Available from publisher's website

In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation vol. 22

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.

APA

Jodele S., Fukuda T., Mizuno K., Vinks A. A., Laskin B. L., Goebel J., Dixon B. P., Chima R. S., Hirsch R., Teusink A., Lazear D., Lane A., Myers K. C., Dandoy C. E. & Davies S. M. (20161102). Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. : Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chicago

Jodele Sonata, Fukuda Tsuyoshi, Mizuno Kana, Vinks Alexander A, Laskin Benjamin L, Goebel Jens, Dixon Bradley P, Chima Ranjit S, Hirsch Russel, Teusink Ashley, Lazear Danielle, Lane Adam, Myers Kasiani C, Dandoy Christopher E and Davies Stella M. 20161102. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. : Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Harvard

Jodele S., Fukuda T., Mizuno K., Vinks A. A., Laskin B. L., Goebel J., Dixon B. P., Chima R. S., Hirsch R., Teusink A., Lazear D., Lane A., Myers K. C., Dandoy C. E. and Davies S. M. (20161102). Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. : Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

MLA

Jodele Sonata, Fukuda Tsuyoshi, Mizuno Kana, Vinks Alexander A, Laskin Benjamin L, Goebel Jens, Dixon Bradley P, Chima Ranjit S, Hirsch Russel, Teusink Ashley, Lazear Danielle, Lane Adam, Myers Kasiani C, Dandoy Christopher E and Davies Stella M. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. : Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20161102.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC